Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 579,355
  • Shares Outstanding, K 70,567
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,700 K
  • EBIT $ -135 M
  • EBITDA $ -140 M
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.98

Options Overview Details

View History
  • Implied Volatility 124.62% ( +9.00%)
  • Historical Volatility 68.79%
  • IV Percentile 75%
  • IV Rank 50.46%
  • IV High 230.00% on 10/18/24
  • IV Low 17.30% on 01/02/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 5
  • Volume Avg (30-Day) 134
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 5,589
  • Open Int (30-Day) 4,730

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.52
  • Number of Estimates 6
  • High Estimate -0.50
  • Low Estimate -0.54
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -6.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.41 +10.80%
on 12/18/24
10.35 -20.68%
on 12/02/24
-0.53 (-6.06%)
since 11/20/24
3-Month
7.41 +10.80%
on 12/18/24
11.53 -28.79%
on 09/23/24
-3.04 (-27.02%)
since 09/20/24
52-Week
6.33 +29.70%
on 06/27/24
16.65 -50.69%
on 03/06/24
-0.32 (-3.75%)
since 12/20/23

Most Recent Stories

More News
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC : 8.21 (+6.76%)
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

BAYRY : 4.9100 (-0.41%)
JNJ : 144.47 (+0.62%)
ORIC : 8.21 (+6.76%)
PFE : 26.36 (+2.29%)
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

ORIC : 8.21 (+6.76%)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC : 8.21 (+6.76%)
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC : 8.21 (+6.76%)
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC : 8.21 (+6.76%)
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC : 8.21 (+6.76%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC : 8.21 (+6.76%)
Why Shares of Oric Pharmaceuticals Jumped Monday

Private investors agreed to spend $85 million to purchase the company's stock.

ORIC : 8.21 (+6.76%)
Pre-Market Brief: Stocks Mixed As Brutal Year Nears End

March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...

ESH23 : 3,957.05s (-0.09%)
META : 585.25 (-1.73%)
AAPL : 254.49 (+1.88%)
SESN : 12.5760 (+7.29%)
HOTH : 0.8100 (+5.21%)
CLLS : 1.6400 (+3.14%)
ORIC : 8.21 (+6.76%)
PFE : 26.36 (+2.29%)
TGTX : 32.20 (+4.04%)

Business Summary

ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 9.30
2nd Resistance Point 8.78
1st Resistance Point 8.49
Last Price 8.21
1st Support Level 7.68
2nd Support Level 7.16
3rd Support Level 6.87

See More

52-Week High 16.65
Fibonacci 61.8% 12.71
Fibonacci 50% 11.49
Fibonacci 38.2% 10.27
Last Price 8.21
52-Week Low 6.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar